Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival

Glioblastoma (GBM) is the most malignant brain tumor where patients' survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet need for novel, effective therapeutic strategies for this devastating disease...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Poli, Aurélie, Wang, Jian, Domingues, Olivia, Planagumà, Jesús, Yan, Tao, Rygh, Cecilie Brekke, Skaftnesmo, Kai Ove, Thorsen, Frits, McCormack, Emmet, Hentges, François, Pedersen, Paal Henning, Zimmer, Jacques, Enger, Per Øyvind, Chekenya, Martha
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2013
Schlagworte:
Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3824525/
https://ncbi.nlm.nih.gov/pubmed/24127551
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge